Literature DB >> 27532369

Symptom burden in mesothelioma patients admitted to home palliative care.

Sebastiano Mercadante1, Daniela Degiovanni2, Alessandra Casuccio3.   

Abstract

CONTEXT: Mesothelioma is a very aggressive cancer that is brought on by asbestos exposure. Because there is a long latency period between exposure to asbestos and symptoms of disease, most patients with mesothelioma present with advanced disease and survive an average of 8-12 months. Thus, best supportive care should be considered critical to optimally manage these patients. AIM: The aim of this study was to examine the epidemiological characteristics and symptom burden of mesothelioma patients when admitted to home palliative care.
METHODS: The charts of a consecutive sample of patients admitted to the home palliative care program with a diagnosis of mesothelioma in an endemic industrialized area were reviewed. The estimated survival time was about two months from admission. Epidemiological characteristics were collected. Karnofsky status, characteristics of pain and analgesic treatment at time of admission were recorded. ESAS (Edmonton Symptom Assessment System) and other clinical problems reported in the charts at admission time were also recorded.
RESULTS: Of the 674 charts reviewed, 56 patients (8.3%) had a diagnosis of mesothelioma. About three quarters of those had pain, with 18 and 2 patients with moderate and severe pain, respectively, despite receiving medium to high doses of opioids. The principal pain site was the chest. Pain was significantly associated with opioid consumption (p < .0005) and dyspnea (p = .049). Symptom burden was relevant, with a global ESAS of about 40. Pain, weakness, poor appetite, poor well-being, and dyspnea were the most frequent symptoms with the highest intensity; cough and pleural effusion were more frequently present as clinical problems.
CONCLUSION: This study shows that mesothelioma is a devastating cancer with a relevant symptom burden, and that patients were referred to palliative care late in the course of their disease, suggesting that earlier integration of palliative care should be considered to relieve suffering in all disease stages - not only at the end of life.

Entities:  

Keywords:  Cancer pain; Dyspnea; Mesothelioma; Palliative care

Mesh:

Substances:

Year:  2016        PMID: 27532369     DOI: 10.1080/03007995.2016.1226165

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Depression and Complicated Grief, and Associated Factors, of Bereaved Family Members of Patients Who Died of Malignant Pleural Mesothelioma in Japan.

Authors:  Yasuko Nagamatsu; Yumi Sakyo; Edward Barroga; Riwa Koni; Yuji Natori; Mitsunori Miyashita
Journal:  J Clin Med       Date:  2022-06-13       Impact factor: 4.964

2.  Bereaved Family Members' Perspectives of Good Death and Quality of End-of-Life Care for Malignant Pleural Mesothelioma Patients: A Cross-Sectional Study.

Authors:  Yasuko Nagamatsu; Yumi Sakyo; Edward Barroga; Riwa Koni; Yuji Natori; Mitsunori Miyashita
Journal:  J Clin Med       Date:  2022-05-01       Impact factor: 4.964

3.  Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: An integrative systematic review.

Authors:  Madeleine Harrison; Clare Gardiner; Bethany Taylor; Stephanie Ejegi-Memeh; Liz Darlison
Journal:  Palliat Med       Date:  2021-04-08       Impact factor: 4.762

4.  Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.

Authors:  Yasuko Nagamatsu; Isao Oze; Keisuke Aoe; Katsuyuki Hotta; Katsuya Kato; Junko Nakagawa; Keiko Hara; Takumi Kishimoto; Nobukazu Fujimoto
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

5.  Malignant Peritoneal Mesothelioma: A Challenging Case for Palliative Care.

Authors:  Carolina Vidal; Inês Romero; Isabel Neto
Journal:  Cureus       Date:  2022-08-01

6.  Dying of mesothelioma: A qualitative exploration of caregiver experiences.

Authors:  Jessica T Lee; Dipti L Mittal; Anne Warby; Steven Kao; Haryana M Dhillon; Janette L Vardy
Journal:  Eur J Cancer Care (Engl)       Date:  2022-06-20       Impact factor: 2.328

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.